BR9712981A - Treatment of HIV and cancer. - Google Patents

Treatment of HIV and cancer.

Info

Publication number
BR9712981A
BR9712981A BR9712981-0A BR9712981A BR9712981A BR 9712981 A BR9712981 A BR 9712981A BR 9712981 A BR9712981 A BR 9712981A BR 9712981 A BR9712981 A BR 9712981A
Authority
BR
Brazil
Prior art keywords
cancer
hiv
treatment
virus
cell
Prior art date
Application number
BR9712981-0A
Other languages
Portuguese (pt)
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR9712981A publication Critical patent/BR9712981A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"TRATAMENTO DE HIV E CâNCER"<D>. Um processo de tratamento de infecção por HIV ou ouras infecções virais pela administração de um herbicida ou fungicida ou derivado dos mesmos a um ser animal ou humano. Os fungicidas ou herbicidas podem ser utilizados em conjunto com outros tratamentos, por exemplo, com AZT ou inibidores de protease para o tratamento de HIV. Por exemplo, foi demonstrado que a o tiabendazol e cloroprofam reduzem rapidamente o nível de produção de vírus a partir de populações celulares cronicamente infectadas com HIV-1 e que o efeito antiviral é mantido com a continuada exposição ao composto. Esta redução na produção de vírus ocorre em concentrações que não são tóxicas para a célula hospedeira e que não têm efeito sobre a síntese de DNA, RNA e proteína celular. Adicionalmente, células cronicamente infectadas tratadas por períodos de tempo prolongados com tiabendazol e cloroprofan não ficaram super-infectadas com HIV. Também é descrito aqui um processo para inibir o crescimento de tumores e canceres em mamíferos compreendendo a administração de um derivado herbicida ou fungicida. Os fungicidas ou herbicidas podem ser utilizados em conjunto com outros tratamentos, por exemplo, taxol para o tratamento de câncer da mama. Também podem ser incluídos potenciadores nas composições herbicidas ou fungicidas. Este processo é particularmente eficaz quando o câncer ou vírus é uma célula animal geneticamente modificada por material genético de planta ou fungo. Também pode ser administrado um agente quimio-terapêutico, primeiro para reduzir o tamanho do câncer, sendo usado a seguir o tratamento com o herbicida ou fungicida. Este processos são particularmente eficazes quando o câncer ou vírus é uma célula mutada compreendendo material genético de planta ou fungo.Invention Patent: <B> "TREATMENT OF HIV AND CANCER" <D>. A process for treating HIV infection or other viral infections by administering an herbicide or fungicide or derivatives thereof to an animal or human. Fungicides or herbicides can be used in conjunction with other treatments, for example, with AZT or protease inhibitors for the treatment of HIV. For example, it has been shown that thiabendazole and chloroprofam quickly reduce the level of virus production from cell populations chronically infected with HIV-1 and that the antiviral effect is maintained with continued exposure to the compound. This reduction in virus production occurs at concentrations that are not toxic to the host cell and that have no effect on the synthesis of DNA, RNA and cellular protein. Additionally, chronically infected cells treated for long periods of time with thiabendazole and chloroprofan did not become super-infected with HIV. Also described herein is a process for inhibiting the growth of tumors and cancers in mammals comprising administering an herbicidal or fungicidal derivative. Fungicides or herbicides can be used in conjunction with other treatments, for example, taxol for the treatment of breast cancer. Enhancers can also be included in herbicidal or fungicidal compositions. This process is particularly effective when the cancer or virus is an animal cell genetically modified by genetic material from a plant or fungus. A chemo-therapeutic agent can also be administered, first to reduce the size of the cancer, being used after the treatment with the herbicide or fungicide. These processes are particularly effective when the cancer or virus is a mutated cell comprising plant or fungal genetic material.

BR9712981-0A 1997-05-16 1997-11-26 Treatment of HIV and cancer. BR9712981A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4672697P 1997-05-16 1997-05-16
PCT/US1997/021564 WO1998051303A1 (en) 1997-05-16 1997-11-26 Hiv and cancer treatment

Publications (1)

Publication Number Publication Date
BR9712981A true BR9712981A (en) 2000-04-18

Family

ID=21945046

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712981-0A BR9712981A (en) 1997-05-16 1997-11-26 Treatment of HIV and cancer.

Country Status (19)

Country Link
EP (1) EP0954309A1 (en)
JP (1) JP2000510156A (en)
KR (1) KR20000049064A (en)
CN (1) CN1254281A (en)
AR (1) AR009968A1 (en)
AU (1) AU7402998A (en)
BR (1) BR9712981A (en)
CA (1) CA2268848A1 (en)
CO (1) CO5070657A1 (en)
CZ (1) CZ124999A3 (en)
HU (1) HUP9904092A3 (en)
IL (1) IL129351A0 (en)
NO (1) NO991701L (en)
PE (1) PE11499A1 (en)
PL (1) PL335160A1 (en)
SK (1) SK46999A3 (en)
TR (1) TR199901530T2 (en)
WO (1) WO1998051303A1 (en)
ZA (1) ZA979095B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
EP1154779A2 (en) * 1999-02-26 2001-11-21 Napro Biotherapeutics, Inc. Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started
CA2366697A1 (en) * 1999-02-26 2000-08-31 Larry Helson Treatment regimen for hormone-sensitive cancers
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
AU2001286744A1 (en) * 2000-08-25 2002-03-04 Beth Israel Deaconess Medical Center Compounds and methods for inhibiting neuronal cell death
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) * 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
EP1330441A2 (en) * 2000-09-26 2003-07-30 The University of Arizona Foundation Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
WO2002041891A2 (en) * 2000-11-01 2002-05-30 The Procter & Gamble Company Hiv treatment with benzimidazoles
JP2004115397A (en) * 2002-09-25 2004-04-15 Fuji Photo Film Co Ltd Liposome comprising therapeutic agent for vascular disease
CN101111248A (en) * 2004-12-06 2008-01-23 新南部创新有限公司 Treatment for cancer
AU2005313839B2 (en) * 2004-12-06 2010-03-11 Pitney Pharmaceuticals Pty Limited Treatment for cancer
US7727967B2 (en) * 2006-02-24 2010-06-01 Boise State University Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines
WO2009043093A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
CN101643729B (en) * 2008-08-07 2011-12-28 复旦大学 Nucleic acid molecule NRN1SR22 and application thereof in preparation of anticancer medicaments
WO2015140792A1 (en) * 2014-03-16 2015-09-24 Hadasit Medical Research Services And Development Ltd. Type iii deiodinase inhibitors and uses thereof
CN105418711A (en) * 2015-11-06 2016-03-23 山东大学 Application of alpha-L-rhamnosidase to preparing hydroxycarbamide and glycoside derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ286412B6 (en) * 1993-03-31 2000-04-12 Merck & Co Inc Synergetic combination of compounds for treating AIDS, pharmaceutical preparation containing such synergetic combination and use of this synergetic combination for preparing pharmaceutical preparation
US5665713A (en) * 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5656615A (en) * 1995-04-12 1997-08-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
BR9604973A (en) * 1995-04-12 1998-06-09 Procter & Gamble A pharmaceutical composition containing n-chlorine phenyl carbamates and n-chlorine phenyl thiocarbamates for inhibiting the growth of viruses and cancers
WO1997005873A2 (en) * 1995-08-04 1997-02-20 The Procter & Gamble Company Use of fluconazole for inhibiting the growth of cancers

Also Published As

Publication number Publication date
WO1998051303A1 (en) 1998-11-19
SK46999A3 (en) 2000-05-16
KR20000049064A (en) 2000-07-25
PL335160A1 (en) 2000-04-10
NO991701D0 (en) 1999-04-09
CZ124999A3 (en) 1999-09-15
AU7402998A (en) 1998-12-08
JP2000510156A (en) 2000-08-08
TR199901530T2 (en) 1999-10-21
AR009968A1 (en) 2000-05-17
CN1254281A (en) 2000-05-24
NO991701L (en) 2000-01-17
IL129351A0 (en) 2000-02-17
CO5070657A1 (en) 2001-08-28
ZA979095B (en) 1998-05-11
CA2268848A1 (en) 1998-11-19
HUP9904092A3 (en) 2000-07-28
PE11499A1 (en) 1999-03-01
EP0954309A1 (en) 1999-11-10
HUP9904092A2 (en) 2000-04-28

Similar Documents

Publication Publication Date Title
BR9712981A (en) Treatment of HIV and cancer.
DK175632B1 (en) Two-phase solvent carrier system
BR9916732A (en) Malnic acid derivatives, process for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity)
BR0313743A (en) Benzimidazole quinolinones and uses of these
Cuce et al. Treatment of paracoccidioidomycosis, candidiasis, chromomycosis, lobomycosis, and mycetoma with ketoconazole
BR0308854A (en) Substituted benzazoles and their uses as raf kinase inhibitors
BR9811055A (en) Compound, use of it, pharmaceutical composition, and process for treating disease or medical condition mediated by factor xa
BRPI0418251B8 (en) phosphonates, monophosphonamidates, bisphosphonamidates, and pharmaceutical composition comprising them
BR9810745A (en) Benzimidazole derivatives
NO20034204D0 (en) Pharmaceutical combinations for the treatment of cancer
BG50372A3 (en) Fungicidal composition a method of combating fungus
BR0207316A (en) Epothilone derivatives for the treatment of refractory tumors
BRPI0412871A (en) combinations of fungicidal active substances
NO974696L (en) Pharmaceutical preparation containing N-chlorophenylcarbamates and N-chlorophenylthiocarbamates for inhibition of virus and cancer growth
BR0114465A (en) Transgenic corn seed treatment with clotianidin
NO20023486L (en) Pyrrole-type compounds, compounds containing compounds and their use in the treatment of cancer and viral diseases
BR9913010A (en) Compound, pharmaceutical composition, and process for the treatment of disorders responsive to the opening of potassium channels activated by highly conductive calcium in a mammal in need.
WO2002064552A8 (en) 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
BR9913990A (en) Use of organophosphate compounds for the production of pharmaceutical preparations for the therapeutic and prophylactic treatment of infections or as a fungicide, bactericide or herbicide in plants
UY26514A1 (en) &#34;COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUES&#34;.
CA2465062A1 (en) Preventive and/or therapeutic agent for viral infection
CO5190659A1 (en) STEROID SAPOGENINS FOR THE CONTROL OF COCCIDIOSIS IN ANIMALS
BR9915639A (en) Use of phosphonoformic acid derivatives to treat infections
BRPI0407271A (en) Anthelmintic composition
ATE110714T1 (en) HYDROXAMIC ACID DERIVATIVES WHICH INHIBIT LIPOXYGENASE.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.